Meanwhile, Ma’s study (Ma et al., 2011) showed that rs2293347 was associated with the efficacy of gefitinib in advanced NSCLC patients, and Zhang et al. (2013) found that the rs2293347 affects the OS of patients with LC in a population in southern China, which are further evidences of the potential of EGFR polymorphisms to guide targeted therapeutic strategies and personalized medicine. Here, EGFR is linked to non-small cell lung carcinoma.